<DOC>
	<DOCNO>NCT00454701</DOCNO>
	<brief_summary>Subjects expose alefacept enrol . Subjects contact every 6 month gather general health information .</brief_summary>
	<brief_title>Assessment Tracking Long-term Alefacept Safety</brief_title>
	<detailed_description>There study-mandated test , visit clinical intervention 1st ( enrol ) visit . After patient enrol study , contact every 6 month complete structure telephone interview conduct ATLAS Study Center .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Psoriasis patient prescribe alefacept consistent product label eligible enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Alefacept</keyword>
	<keyword>AmeviveÂ®</keyword>
	<keyword>Drug exposure</keyword>
</DOC>